Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

This study assessed the immunogenicity and safety of the BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer treatment. We enrolled lung cancer patients receiving anticancer treatment and non-cancer patients; all participants were fully vaccinated with the BNT162b2 vaccine. Blood samp...

Full description

Bibliographic Details
Main Authors: Kei Nakashima, Masayuki Ishida, Hiroki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku, Yuko Nitahara, Yasutoshi Kido, Yoshio Hirota
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
anticancer treatment
coronavirus disease vaccine
immunogenicity
lung cancer
vaccine safety
Online Access:http://dx.doi.org/10.1080/21645515.2022.2140549

Internet

http://dx.doi.org/10.1080/21645515.2022.2140549

Similar Items